Skip to main content
Premium Trial:

Request an Annual Quote

Ciphergen, Novartis Expand Compound Profiling Deal

SAN FRANCISCO, Nov. 5 - Ciphergen Biosystems said today it expanded an agreement with Novartis to conduct compound profiling for the pharmaceutical company.


Ciphergen will use its SELDI ProteinChip systems and Biomarker Discovery Centers to evaluate samples for Novartis, according to the company.


Financial details of the agreement were not disclosed.


Ciphergen said the first project is a study with Novartis' oncology business unit to compare serum samples of responder and nonresponder patients given candidate drug treatment.


Click here for more information.


The Scan

Follow-Up Data Requests to Biobank Participants Ineffective, Study Finds

An effort to recontact biobank enrollees for additional information reports low participation in a new BMJ Open study.

Study Finds Widespread Transmission of Resistant Bacteria in Vietnam Hospitals

A sequencing study in The Lancet Microbe finds widespread transmission of drug-resistant Escherichia coli, Klebsiella pneumoniae, and Acinetobacter baumannii in two Vietnam ICUs.

Novel Brain Cell Organoids Show Promise for Autism Research

University of Utah researchers report in Nature Communications on their development of brain cell organoids to study SHANK3-related autism.

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.